Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.885424
Abstract: Claudin 18.2 (CLDN18.2), a tight junction (TJ) family protein controlling molecule exchange between cells, is frequently over-expressed in gastric cancer, pancreatic adenocarcinomas and in a fraction of non–small cell lung cancer cases. The tumor properties… read more here.
Keywords: positive cancers; cldn18; humanized vhh; development humanized ... See more keywords